PaySign’s Strong Growth Potential and Strategic Positioning Earns Buy Rating from Analyst

Analyst Gary Prestopino of Barrington maintained a Buy rating on PaySign (PAYS – Research Report), boosting the price target to $6.50.

Gary Prestopino has given his Buy rating due to a combination of factors that highlight PaySign’s strong growth potential and strategic positioning in the market. PaySign is a vertically integrated provider of specialized financial services, particularly in the pharmaceutical and plasma donation industries, offering innovative technology solutions that cater to patient affordability and prepaid card programs. The company’s Patient Affordability segment has shown remarkable growth, with revenue increasing significantly and margins improving, which has contributed to a higher consolidated gross margin and adjusted EBITDA margin.
Furthermore, the Patient Affordability segment has been expanding its reach by adding new programs, with expectations of doubling its revenue in 2025. Despite a decline in plasma revenue due to industry-wide oversupply, PaySign continues to expand its plasma centers and enhance its offerings through strategic acquisitions like Gamma Innovation, which adds valuable technology-driven solutions. The company’s increased guidance for total revenues and adjusted EBITDA reflects confidence in its growth trajectory, supporting the Buy rating with a price target range of $6-7.

In another report released today, Lake Street also reiterated a Buy rating on the stock with a $7.00 price target.